Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma

European Journal of Endocrinology

Volumn 166, Issue 3, 2012, Pages 451-458

  Berruti, Alfredo ^b   Sperone, Paola ^b   Ferrero, Anna ^b   Germano, Antonina ^a   Ardito, Arianna ^a   Priola, Adriano Massimiliano ^a   De Francia, Silvia ^a   Volante, Marco ^a   Daffara, Fulvia ^a   Generali, Daniele ^c   Leboulleux, Sophie ^d   Perotti, Paola ^b   Baudin, Eric ^d   Papotti, Mauro ^a   Terzolo, Massimo ^a  

^a Internal Medicine   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c CREMONA HOSPITAL   (Italy)

^d INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CARBOPLATIN; CISPLATIN; ETOPOSIDE; GEMCITABINE; MITOTANE; PACLITAXEL; SORAFENIB; STREPTOZOCIN;

ADRENAL CORTEX CARCINOMA; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CELL VIABILITY; CHEMOTHERAPY INDUCED EMESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIARRHEA; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; HEMATOLOGIC DISEASE; HUMAN; HYPOCALCEMIA; HYPOPHOSPHATEMIA; IN VITRO STUDY; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SALVAGE THERAPY; SKIN DISEASE; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; PROSPECTIVE STUDIES; PYRIDINES;

EID: 84857943100     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-11-0918     Document Type: Article

References (30)

1. Crucitti F, Bellantone R, Ferrante A, Boscherini M & Crucitti P. The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. Surgery 1996 119 161-170. (doi:10.1016/S0039-6060(96)80164-4)
2. Allolio B & Fassnacht M. Clinical review: adrenocortical carcinoma: clinical update. Journal of Clinical Endocrinology and Metabolism 2006 91 2027-2037. (doi:10.1210/jc.2005-2639)
3. Assié G, Antoni G, Tissier F, Caillou B, Abiven G, Gicquel C, Leboulleux S, Travagli JP, Dromain C, Bertagna X, Bertherat J, Schlumberger M & Baudin E. Prognostic parameters of metastatic adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism 2007 92 148-154. (doi:10.1210/jc.2006-0706)
4. Berruti A, Ferrero A, Sperone P, Daffara F, Reimondo G, Papotti M, Dogliotti L, Angeli A & Terzolo M. Emerging drugs for adrenocortical carcinoma. Expert Opinion on Emerging Drugs 2008 13 497-509. (doi:10.1517/14728214.13.3.497)
5. Kerbel RS & Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nature Reviews. Cancer 2004 4 423-436. (doi:10.1038/nrc1369)
6. Bocci G, Nicolaou KC & Kerbel RS. Protracted low-dose effects on human endothelial cell prolipheration and survival in vitro reveal a selective antiangiogenetic window for various chemotherapeutic drugs. Cancer Research 2002 62 638-643. (doi:10.1007/978-3-540-78281-0-10)
7. Emmenegger U, Man S, Shaked Y, Francia G, Wong JW, Hicklin DJ & Kerbel RS. A comparative analysis of low dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Research 2004 64 3994-4000. (doi:10.1158/0008-5472.CAN-04-0580)
8. Emmenegger U, Francia G, Shaked Y & Kerbel RS. Metronomic chemotherapy: principles and lessons learned from applications in the treatment of metastatic prostate cancer. Recent Results in Cancer Research 2010 180 165-183.
9. Wiseman LR & Spencer CM. Paclitaxel: an update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers. Drugs & Aging 1998 12 305-334. (doi:10.2165/00002512-199812040- 00005)
10. Fallo F, Pilon C, Barzon L, Pistorello M, Pagotto U, Altavilla G, Boscaro M & Sonino N. Paclitaxel is an effective antiproliferative agent on the human NCI-H295 adrenocortical carcinoma cell line. Chemotherapy 1998 44 129-134. (doi:10.1159/000007104)
11. Green MC, Buzdar AU & Smith T. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. Journal of Clinical Oncology 2005 23 5983-5992. (doi:10.1200/JCO.2005.06.232)
12. Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom P, Gipson G, Burstein H, Lake D, Shapiro CL, Ungaro P, Norton L, Winer E & Hudis C. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of cancer and leukemia group B protocol 9840. Journal of Clinical Oncology 2008 26 1642-1649. (doi:10.1200/JCO.2007.11.6699)
13. Cazejust J, De Baère T, Auperin A, Deschamps F, Hechelhammer L, Abdel-Rehim M, Schlumberger M, Leboulleux S & Baudin E. Transcatheter arterial chemoembolization for liver metastases in patients with adrenocortical carcinoma. Journal of Vascular and Interventional Radiology 2010 21 1527-1532. (doi:10.1016/j.jvir.2010.05.020)
14. Bernini GP, Moretti A, Bonadio AG, Menicagli M, Viacava P, Naccarato AG, Iacconi P, Miccoli P & Salvetti A. Angiogenesis in human normal and pathologic adrenal cortex. Journal of Clinical Endocrinology and Metabolism 2002 287 4961-4965. (doi:10.1210/jc.2001-011799)
15. Wilhelm SM, Carter C, Tang L, Wilkie D, Mcnabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE &Bollag G. BAY43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Research 2004 64 7099-7109. (doi:10.1158/0008-5472.CAN-04-1443)
16. Hasskarl J. Sorafenib. Cancer Research 2010 184 61-70.
17. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P & Kerbel RS. Continuous low dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. Journal of Clinical Investigation 2000 105 R15-R24. (doi:10.1172/JCI8829)
18. Browder T, Butterfield CE, Kraling BM, Marshall B, O'Reilly MS &Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Research 2000 60 1878-1886. (Pubitemid 30207647)
19. Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, Groshen S, Swenson S, Markland F, Gandara D, Scudder S, Morgan R, Chen H, Lenz HJ & Oza AM. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. Journal of Clinical Oncology 2008 26 76-82. (doi:10.1200/JCO.2007.12.1939)
20. Dellapasqua S, Bertolini F, Bagnardi V, Campagnoli E, Scarano E, Torrisi R, Shaked Y, Mancuso P, Goldhirsch A & Rocca A. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. Journal of Clinical Oncology 2008 26 4899-4905. (doi:10.1200/JCO.2008.17.4789)
21. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT &Christian MC. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute 2000 92 205-216. (doi:10.1093/jnci/92.3.205)
22. De Francia S, Pirro E, Zappia F, De Martino F, Sprio AE, Daffara F, Terzolo M, Berruti A, Di Carlo F & Ghezzo F. A new simple HPLC method for measuring mitotane and its two principal metabolites. Tests in animals and mitotane-treated patients. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2006 837 69-75. (doi:10.1016/j.jchromb. 2006.04.005)
23. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials 1989 10 1-10. (doi:10.1016/0197-2456(89)90015-9)
24. de Fraipont F, El Atifi M, Gicquel C, Bertagna X, Chambaz EM &Feige JJ. Expression of the angiogenesis markers vascular endothelial growth factor-A, thrombospondin-1, and plateletderived endothelial cell growth factor in human sporadic adrenocortical tumors: correlation with genotypic alterations. Journal of Clinical Endocrinology and Metabolism 2000 85 4734-4741. (doi:10.1210/jc.85. 12.4734)
25. Wortmann S, Quinkler M, Ritter C, Kroiss M, Johanssen S, Hahner S, Allolio B & Fassnacht M. Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. European Journal of Endocrinology 2010 162 349-356. (doi:10.1530/EJE-09-0804)
26. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, Inoue M, Bergers G, Hanahan D & Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009 15 220-231. (doi:10.1016/j.ccr.2009.01.027)
27. Steeg PS. Angiogenesis inhibitors: motivators of metastasis? Nature Medicine 2003 9 822-823. (doi:10.1038/nm0703-822)
28. Peinado H & Cano A. A hypoxic twist in metastasis. Nature Cell Biology 2008 10 253-254. (doi:10.1038/ncb0308-253)
29. Sperone P, Ferrero A, Daffara F, Priola A, Zaggia B, Volante M, Santini D, Vincenzi B, Badalamenti G & Intrivici C. Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocrine-Related Cancer 2010 17 445-453. (doi:10.1677/ERC-09-0281)
30. Hahner S & Fassnacht M. Mitotane for adrenocortical carcinoma treatment. Current Opinion in Investigational Drugs 2005 6 386-394. (Pubitemid 40561415)